Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

This study found no statistically significant association between the use of 5α-reductase inhibitors and male breast cancer incidence.

This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.

This study found that both finasteride and dutasteride act as slow, time-dependent inhibitors of steroid 5α-reductase type II, with dutasteride being more efficient, influenced by the enzyme's genetic variants.

This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.

This study found that the solubilities of flutamide, dutasteride, and finasteride in supercritical carbon dioxide were effectively modeled using semiempirical equations by Chrastil and Bartle, with varying levels of accuracy.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This study found that dutasteride more effectively inhibited androgen receptor signaling and reduced cell growth compared to finasteride in prostate cancer cell models, with varying sensitivities across different cell lines.

In a randomized study, men treated with dutasteride for androgenetic alopecia experienced sexual adverse events at twice the rate of those on placebo during 24 weeks, but these events were mild, moderate, and resolved after treatment.

This study found that combining oral testosterone with dutasteride increased testosterone bioavailability in hypogonadal men while suppressing dihydrotestosterone levels over a 28-day period.

This study reported the development of two highly sensitive ELISA assays to detect banned substances finasteride and dutasteride in human urine, offering better sensitivity than existing HPLC/MS/MS methods.

This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.

The source does not provide an abstract for this letter to the editor, so specific results regarding the long-term efficacy and safety of dutasteride for male androgenetic alopecia are not reported.

This study found that dutasteride is not associated with an increased risk of osteoporosis or fractures in older men compared to finasteride, suggesting dutasteride does not adversely affect bone health.

This study found that five 0.1 mg dutasteride capsules are bioequivalent to one 0.5 mg dutasteride capsule in healthy adult males under fasting conditions, and both were well tolerated.

This cohort study using real-world data found no significant difference in the risk of developing prostate cancer between finasteride and dutasteride among patients with benign prostatic hyperplasia, despite previous suggestions that dutasteride might be more effective.

This review discusses emerging therapies for androgenetic alopecia, including topical finasteride, oral minoxidil, and intradermal dutasteride, and reports no clinical results; the authors highlight changes in treatment approaches.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.

This study established a new reverse-phase high-performance liquid chromatography method to accurately and precisely quantify silodosin and dutasteride in mixtures, meeting International Council of Harmonization validation criteria for stability, sensitivity, and recovery.

This study developed a topical dutasteride-loaded Insitu-emulgel for treating androgenetic alopecia, finding it effectively controls drug release, enhances skin penetration, and may improve patient compliance compared to traditional topical treatments, though further clinical research is underway.

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.

In this study, researchers developed and evaluated a topical dutasteride gel for treating male pattern baldness, finding that a formulation with 10% garlic extract showed the most promising results in promoting faster hair growth compared to other formulations tested.

In this study, dutasteride was found to be effective and safe in treating androgenetic alopecia in men who did not respond to finasteride, with improvements observed in hair loss and quality over 24 weeks.

This study developed a validated HPLC method for accurately estimating dutasteride and its related compounds in capsules, suitable for routine and stability sample analysis.

This paper describes a new scalable synthesis method for Dutasteride, highlighting its potential for large-scale commercial production.

This abstract outlines a study evaluating dutasteride's effect on perioperative bleeding during transurethral resection of the prostate, but does not report any new clinical results.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This paper discusses the effect of dutasteride on prostate cancer detection in men with benign prostatic hyperplasia but provides no new clinical results.